SciSparc Ltd. Ordinary Shares - SPRC STOCK NEWS

SciSparc (Nasdaq: SPRC) has announced promising results from a study on 5-methoxy-2-aminoindane (MEAI), conducted in collaboration with Clearmind Medicine Inc. (Nasdaq: CMND). The study, published in ACS Pharmacology and Translational Science, demonstrates MEAI's potential as a novel weight loss drug. Key findings include:

• Significant weight loss in diet-induced obese mice
• Improved glucose metabolism and increased energy expenditure
• Decreased fatty liver and reduced fat accumulation
• Well-tolerated combination treatment with elevated metabolic processes

This research is part of SciSparc and Clearmind's ongoing collaboration since 2022, focusing on developing innovative treatments for addictions, obesity, and metabolic syndrome by combining SciSparc's Palmitoylethanolamide (PEA) with Clearmind's MEAI.

SciSparc (Nasdaq: SPRC) announced that its venture, MitoCareX Bio , has validated the potential significant involvement of its target SLC25 carrier protein in Non-Small Cell Lung Cancer (NSCLC) cells. The discovery was demonstrated using genetic manipulations and 3D spheroid systems, mimicking human solid tumors. NSCLC, accounting for 80%-85% of all lung cancer cases globally, is projected to reach a market value of $59.77 billion by 2030.

MitoCareX previously screened millions of small molecules using its proprietary MITOLINE™ algorithm, identifying potential anti-cancer treatments. The company is now working on creating a predictive AI model to more efficiently discover novel anti-cancer small molecule scaffolds targeting its SLC25 protein of interest.

SciSparc (Nasdaq: SPRC) has signed a non-binding letter of intent (LOI) for the exclusive global out-licensing of its SCI-160 pain treatment program. The deal, valued at approximately $6 million, includes:

1. $3 million in ordinary shares and pre-funded warrants of the undisclosed biotechnology company

2. Potential additional payments and execution fees of about $3 million in cash, subject to meeting certain milestones

SCI-160 is a proprietary synthetic cannabinoid formulation that has shown promising results in pre-clinical studies, demonstrating analgesic effects comparable to high-dose morphine without significant side effects. This development aligns with efforts to address the opioid crisis, as prescription opioid-related deaths have increased significantly since 1999.

SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company, has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement. The company's stock must maintain a minimum bid price of $1.00 per share to remain listed. SciSparc has been granted a 180-day grace period, until January 13, 2025, to regain compliance.

To comply, the closing bid price of SPRC shares must be at least $1.00 for a minimum of ten consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day compliance period. Failure to meet requirements could result in delisting from Nasdaq. The notice does not immediately affect SciSparc's listing or trading of its ordinary shares.

SciSparc (Nasdaq: SPRC) has announced the submission of a new patent application to the USPTO for a novel composition combining Palmitoylethanolamide (PEA), the active ingredient in their CannAmide™ product, with Clearmind Medicine's MEAI compound. This innovative formulation aims to treat metabolic syndrome and obesity.

The patent application is part of an ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) and was developed in conjunction with Professor Joseph Tam from the Hebrew University. This marks the thirteenth patent application filed under this partnership, targeting various disorders including alcohol use disorder and cocaine addiction.

The obesity treatment market, valued at $15 billion in 2022, is expected to grow at a 10.0% CAGR. With obesity affecting 41.9% of U.S. adults aged 20 and over, this new treatment could address a significant health concern and market opportunity.

SciSparc announced signing a non-binding letter of intent (LOI) to spin off its advanced clinical-stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals to Miza III Ventures. Valued at $11.6 million, the assets will be exchanged for 63.3 million Miza shares and up to 48 million contingent rights. The deal's final terms will determine SciSparc's controlling stake in Miza, estimated between 75% and 84.53%. The transaction aligns with SciSparc's strategy to enhance shareholder value and follows a merger agreement with AutoMax Motors. Key portfolio assets include SCI-110 for Tourette syndrome and Alzheimer's disease, and SCI-210 for autism.

SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company, announced the European Patent Office granted its patent application for 'Compositions and Methods of Potentiating Antimicrobials'. This patent, which complements a similar U.S. patent, enhances SciSparc's intellectual property portfolio and competitive edge in the pharmaceutical industry. The patent covers pharmaceutical compositions combining antibiotics and cannabinoids, potentially addressing antimicrobial resistance. SciSparc is actively expanding its intellectual property globally, with recent patents in Canada and Europe, reflecting its commitment to innovation. The company’s portfolio now spans major markets including the U.S., Europe, Japan, Australia, and Israel, encompassing nine patent families and two trademarks.

SciSparc (Nasdaq: SPRC) announces a merger agreement with AutoMax Motors , a leading vehicle importer in Israel. The deal entails SciSparc acquiring 100% of AutoMax, forming a new Israeli subsidiary. Shareholders will hold 50.01% of the Combined Company post-merger. The Acquisition aims to maximize shareholder value following a strategic review in 2022. The deal is subject to regulatory approvals and shareholder agreement.

SciSparc announces collaboration with Clearmind Medicine Inc. for novel therapy to treat depression. Clearmind submits patent application for MEAI compound combined with SciSparc's CannAmide™. Global depression and anxiety disorders treatment market expected to reach USD 41.83 billion by 2034.